Therapeutic drug monitoring in cancer - Are we missing a trick?

European Journal of Cancer

Volumn 50, Issue 12, 2014, Pages 2005-2009

  Bardin, Christophe ^a   Veal, Gareth ^b   Paci, Angelo ^c   Chatelut, Etienne ^d   Astier, Alain ^e   Levêque, Dominique ^f   Widmer, Nicolas ^g,h   Beijnen, Jos ⁱ  

^a Institut Cochin   (France)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f HÔPITAL DE HAUTEPIERRE   (France)

^g UNIVERSITY OF LAUSANNE   (Switzerland)

^h Clinical Pharmacy Pharmacie des Hôpitaux de l'Est Lémanique   (Switzerland)

ⁱ NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Chemotherapy; Cytotoxics; Monoclonal antibodies; Oncology; Pharmacokinetics; Target concentration; Targeted therapies; Therapeutic drug monitoring; Tyrosine kinase inhibitors; Variability

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CYTOTOXIC AGENT; DASATINIB; ERLOTINIB; FLUOROURACIL; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; MONOCLONAL ANTIBODY; NILOTINIB; PROTEIN KINASE INHIBITOR; RITUXIMAB; SORAFENIB; SUNITINIB; TAMOXIFEN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PRACTICE; DOSE RESPONSE; DRUG MONITORING; HUMAN; MEDICATION COMPLIANCE; MOLECULARLY TARGETED THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL;

CHEMOTHERAPY; CYTOTOXICS; MONOCLONAL ANTIBODIES; ONCOLOGY; PHARMACOKINETICS; TARGET CONCENTRATION; TARGETED THERAPIES; THERAPEUTIC DRUG MONITORING; TYROSINE KINASE INHIBITORS; VARIABILITY;

ANTINEOPLASTIC AGENTS; CYTOTOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; NEOPLASMS;

EID: 84904067562     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.04.013     Document Type: Article

References (25)

1. M. Saleem, G. Dimeski, C.M. Kirkpatrick, P.J. Taylor, and J.H. Martin Target concentration intervention in oncology: where are we at? Ther Drug Monit 34 2012 257 265
2. J.H. Beijnen, and H. Rosing Bioanalytical methods for anticancer drugs J.H.M. Schellens, H.L. McLeod, D.R. Newell, Cancer clinical pharmacology 2005 Oxford University Press Oxford 1 17
3. W.E. Evans, M.V. Relling, J.H. Rodman, W.R. Crom, J.M. Boyett, and C.H. Pui Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia New Engl J Med 338 1998 499 505
4. R. Fety, F. Rolland, and M. Barberi-Heyob et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicenter randomized trial in patients with locally advanced head and neck carcinomas Clin Cancer Res 4 1998 2039 2045
5. E. Gamelin, R. Delva, and J. Jacob et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial in patients with metastatic colorectal cancer J Clin Oncol 26 2008 2009 2105
6. C. Sawyers Targeted cancer therapy Nature 432 2004 294 297
7. G. Giamas, and Y.L. Man et al. Kinases as targets in the treatment of solid tumors Cell Signal 22 2010 984 1002
8. V.C. Jordan Tamoxifen: catalyst for the change to targeted therapy Eur J Cancer 44 2008 30 38
9. J.H. Beijnen, and J.H.M. Schellens Personalized medicine in oncology: a personal view with myths and facts Curr Clin Pharmacol 5 2010 141 147
10. S.P. Davies, H. Reddy, M. Caivano, and P. Cohen Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem J 351 2000 95 105
11. D.R. Mould, and B. Green Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development BioDrugs 24 2010 23 39
12. M. Von Mehren, and N. Widmer Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 37 2011 291 299
13. H.J. Klumpen, and C.F. Samer et al. Moving towards dose individualization of tyrosine kinase inhibitors Cancer Treat Rev 37 2011 251 260
14. B. Gao, S. Yeap, A. Clements, B. Balakrishnar, M. Wong, and H. Gurney Evidence for therapeutic drug monitoring of targeted anticancer therapies J Clin Oncol 30 2012 4017 4025
15. N.L. Dirks, and B. Meibohm Population pharmacokinetics of therapeutic monoclonal antibodies Clin Pharmacokinet 49 2010 633 659
16. H. Yu, N. Steeghs, M. Nijenhuis, J.H.M. Schellens, J.H. Beijnen, and A.D.R. Huitema Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors; focus on the pharmacokinetic targets Clin Pharmacokinet 53 2014 305 335
17. S.D. Horne, J.B. Stevens, and B.Y. Abdallah et al. Why imatinib remains an exception of cancer research J Cell Physiol 228 2013 665 670
18. S. Picard, K. Titier, and G. Etienne et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood 109 2007 3496 3499
19. G.D. Demetri, Y. Wang, and E. Wehrle et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors J Clin Oncol 27 2009 3141 3147
20. T. Buclin, N. Widmer, J. Biollaz, and L.A. Decosterd Who is in charge of assessing therapeutic drug monitoring? The case of imatinib Lancet Oncol 12 2011 9 11
21. M. Saleem, G. Dimeski, C.M. Kirkpatrick, P.J. Taylor, and J.H. Martin Target concentration intervention in oncology: where are we at? Ther Drug Monit 34 2012 257 265
22. V. Gotta, T. Buclin, C. Csajka, and N. Widmer Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes Ther Drug Monit 35 2013 150 167
23. M. Baccarani, S. Pileri, J.L. Steegmann, M. Muller, S. Soverini, M. Dreyling ESMO Guidelines Working Group Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 23 Suppl. 7 2012 vii72 vii77
24. D.H. Josephs, D.S. Fisher, J. Spicer, and R.J. Flanagan Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring Ther Drug Monit 35 2013 562 587
25. J.H. Beumer Without therapeutic drug monitoring, there is no personalized cancer care Clin Pharmacol Ther 93 2013 228 230